Columbia Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.69M Sell
34,525
-804
-2% -$173K 1.51% 17
2026
Q1
$7.68M Sell
35,329
-155
-0.4% -$34.4K 1.46% 16
2025
Q4
$8.11M Sell
35,484
-220
-0.6% -$50.1K 1.44% 17
2025
Q3
$8.27M Sell
35,704
-774
-2% -$158K 1.55% 14
2025
Q2
$6.77M Sell
36,478
-874
-2% -$162K 1.33% 15
2025
Q1
$7.83M Sell
37,352
-1,304
-3% -$254K 1.53% 14
2024
Q4
$6.87M Sell
38,656
-2,122
-5% -$390K 1.26% 16
2024
Q3
$8.05M Buy
40,778
+241
+0.6% +$45K 1.4% 17
2024
Q2
$6.95M Buy
40,537
+172
+0.4% +$28.5K 1.3% 20
2024
Q1
$6.25M Hold
40,365
1.27% 18
2023
Q4
$6.25M Sell
40,365
-71
-0.2% -$10.4K 1.27% 18
2023
Q3
$6.03M Sell
40,436
-366
-0.9% -$53.7K 1.33% 18
2023
Q2
$5.5M Sell
40,802
-5,484
-12% -$804K 1.17% 23
2023
Q1
$7.38M Sell
46,286
-864
-2% -$132K 1.66% 12
2022
Q4
$7.62M Sell
47,150
-265
-0.6% -$40.6K 1.85% 12
2022
Q3
$6.36M Sell
47,415
-1,243
-3% -$178K 1.67% 12
2022
Q2
$7.45M Buy
+48,658
New +$7.44M 1.89% 11
2021
Q4
$7.53M Buy
55,613
+445
+0.8% +$52.6K 1.53% 15
2021
Q3
$5.95M Buy
55,168
+781
+1% +$89.2K 1.3% 17
2021
Q2
$6.13M Sell
54,387
-7,740
-12% -$872K 1.36% 17
2021
Q1
$6.72M Buy
62,127
+5,867
+10% +$628K 1.22% 23
2020
Q4
$6.03M Buy
56,260
+1,155
+2% +$111K 1.21% 25
2020
Q3
$4.83M Sell
55,105
-1,129
-2% -$106K 1.11% 31
2020
Q2
$5.52M Sell
56,234
-44,655
-44% -$3.93M 1.32% 23
2020
Q1
$47.7M Buy
100,889
+51,440
+104% +$4.38M 11.77% 1
2019
Q4
$43.8K Buy
49,449
+2,402
+5% +$199K 1.06% 31
2019
Q3
$3.56M Buy
47,047
+3,440
+8% +$236K 0.93% 37
2019
Q2
$3.17M Buy
43,607
+7,191
+20% +$565K 0.83% 39
2019
Q1
$2.94M Buy
36,416
+1,807
+5% +$148K 0.78% 40
2018
Q4
$3.19M Buy
34,609
+1,365
+4% +$120K 0.97% 32
2018
Q3
$3.14M Buy
33,244
+571
+2% +$54.1K 0.82% 41
2018
Q2
$3.03M Buy
32,673
+2,983
+10% +$291K 0.88% 40
2018
Q1
$2.81M Sell
29,690
-205
-0.7% -$22.5K 0.82% 43
2017
Q4
$2.89M Sell
29,895
-525
-2% -$49.5K 0.83% 41
2017
Q3
$2.7M Buy
30,420
+431
+1% +$32.8K 0.83% 40
2017
Q2
$2.17M Buy
29,989
+100
+0.3% +$6.72K 0.7% 43
2017
Q1
$1.95M Buy
29,889
+300
+1% +$18.9K 0.65% 48
2016
Q4
$1.85M Buy
29,589
+1,029
+4% +$62.8K 0.63% 48
2016
Q3
$1.8M Buy
28,560
+1,062
+4% +$68.8K 0.63% 48
2016
Q2
$1.7M Buy
27,498
+5
+0% +$305 0.61% 48
2016
Q1
$1.57M Buy
27,493
+1,110
+4% +$61.9K 0.58% 49
2015
Q4
$1.56M Buy
26,383
+35
+0.1% +$2.02K 0.63% 46
2015
Q3
$1.43M Sell
26,348
-475
-2% -$30.9K 0.58% 51
2015
Q2
$1.8M Buy
26,823
+200
+0.8% +$13.1K 0.69% 43
2015
Q1
$1.56M Hold
26,623
0.59% 51
2014
Q4
$1.74M Sell
26,623
-155
-0.6% -$9.77K 0.67% 45
2014
Q3
$1.55M Sell
26,778
-200
-0.7% -$11.1K 0.62% 49
2014
Q2
$1.52M Hold
26,978
0.62% 51
2014
Q1
$1.39M Hold
26,978
0.6% 54
2013
Q4
$1.43M Buy
+26,978
New +$1.33M 0.63% 49

Other funds holding ABBV

Columbia Asset Management's ABBV Position: Q2 2026 in Review

Columbia Asset Management reduced its AbbVie (ABBV) stake by 2.3% in Q2 2026, selling an estimated $173K and leaving 34,525 shares worth $8.69M. The position accounts for 1.51% of the portfolio, ranked #17.

Columbia Asset Management first reported a position in ABBV in Q4 2013 and has held it in 50 quarters since. The position peaked at $47.7M in Q1 2020. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Columbia Asset Management held 34,525 shares of AbbVie worth $8.69M as of Q2 2026.
  • Columbia Asset Management sold 804 AbbVie shares in Q2 2026, an estimated $173K.
  • AbbVie made up 1.51% of Columbia Asset Management's portfolio in Q2 2026, its #17 holding.
  • Columbia Asset Management first reported a position in AbbVie in Q4 2013 and has held it in 50 quarters since.
  • Columbia Asset Management's AbbVie position peaked at $47.7M in Q1 2020.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Columbia Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.